Kintor Pharmaceutical Limited (HKG:9939)
Hong Kong · Delayed Price · Currency is HKD 1.665
-0.025 (-1.48%)
Aug 27, 2026, 4:08 PM HKT
Kintor Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 32.74 | 147.42 | 445.5 | 865.08 | 930.15 |
Short-Term Investments | - | - | 12.56 | 11.88 | 126.58 |
Cash & Short-Term Investments | 32.74 | 147.42 | 458.05 | 876.96 | 1,057 |
Cash Growth | -77.79% | -67.82% | -47.77% | -17.01% | -24.15% |
Accounts Receivable | 2.8 | - | - | - | - |
Other Receivables | 1.13 | 15.65 | 6.48 | - | - |
Receivables | 3.93 | 15.65 | 6.48 | - | - |
Inventory | 12.09 | 2.22 | - | 603.5 | 351.36 |
Restricted Cash | 2.03 | 0.43 | 0.43 | 5.64 | 1.66 |
Other Current Assets | 4.46 | 6.02 | 7.6 | 21.77 | 116.15 |
Total Current Assets | 55.25 | 171.73 | 472.56 | 1,508 | 1,526 |
Property, Plant & Equipment | 158.02 | 174.23 | 221.84 | 282.48 | 262.3 |
Long-Term Investments | 16.25 | 16.57 | 18 | 17.95 | - |
Other Intangible Assets | 107.26 | 148.95 | 148.94 | 235.65 | 235.62 |
Other Long-Term Assets | 4.03 | 3.65 | 7.9 | 11.2 | 44.17 |
Total Assets | 340.81 | 515.13 | 869.23 | 2,055 | 2,068 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 32.12 | 40.96 | 81.6 | 180.4 | 172.96 |
Accrued Expenses | 3.77 | 5.08 | 17.32 | 19.89 | 25.12 |
Short-Term Debt | 65 | 14.38 | 20 | 40 | - |
Current Portion of Long-Term Debt | 20 | 97.38 | 93.7 | 58.9 | 7.4 |
Current Portion of Leases | 0.61 | 1.25 | 4.53 | 4.44 | 2.07 |
Other Current Liabilities | 6.08 | 7.63 | 7.58 | 14.5 | 12.2 |
Total Current Liabilities | 127.58 | 166.68 | 224.73 | 318.13 | 219.74 |
Long-Term Debt | - | 20 | 133.4 | 177.6 | 147.5 |
Long-Term Leases | 0.99 | - | 2.29 | 5.45 | 2.76 |
Long-Term Unearned Revenue | 2.97 | 3.32 | 19.66 | 19.95 | 4.01 |
Long-Term Deferred Tax Liabilities | 26.68 | 31.04 | 31.04 | 38.82 | 38.82 |
Total Liabilities | 158.21 | 221.05 | 411.12 | 559.95 | 412.83 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.35 | 0.32 | 0.32 | 0.32 | 0.27 |
Additional Paid-In Capital | 4,318 | 4,210 | 4,182 | 4,104 | 3,359 |
Retained Earnings | -4,140 | -3,940 | -3,785 | -2,724 | -1,769 |
Comprehensive Income & Other | 4.47 | 23.58 | 60.73 | 114.77 | 65.49 |
Shareholders' Equity | 182.6 | 294.08 | 458.11 | 1,495 | 1,655 |
Total Liabilities & Equity | 340.81 | 515.13 | 869.23 | 2,055 | 2,068 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 86.6 | 133.01 | 253.92 | 286.39 | 159.73 |
Net Cash (Debt) | -53.86 | 14.41 | 204.13 | 590.57 | 897 |
Net Cash Growth | - | -92.94% | -65.43% | -34.16% | -23.43% |
Net Cash Per Share | -0.12 | 0.03 | 0.48 | 1.57 | 2.52 |
Filing Date Shares Outstanding | 493.81 | 434.2 | 439.4 | 447.5 | 387.59 |
Total Common Shares Outstanding | 493.81 | 434.2 | 439.4 | 447.5 | 387.59 |
Working Capital | -72.33 | 5.05 | 247.83 | 1,190 | 1,306 |
Book Value Per Share | 0.37 | 0.68 | 1.04 | 3.34 | 4.27 |
Tangible Book Value | 75.34 | 145.13 | 309.17 | 1,260 | 1,420 |
Tangible Book Value Per Share | 0.15 | 0.33 | 0.70 | 2.81 | 3.66 |
Buildings | 131.74 | 88.88 | 89.23 | 89.23 | 57.66 |
Machinery | 70.63 | 53.66 | 58.7 | 58.24 | 46.78 |
Construction In Progress | - | 62 | 109.24 | 105.66 | 125.74 |